摘要:
The present invention aims at establishing a means for obtaining highly pure virus-like particles by a simple method. There is provided a production method for culture containing virus-like particles, comprising: transforming insect cells with baculovirus vector containing a viral nucleic acid sequence; and cultivating the insect cells, wherein the culture is obtained after continuing cultivating the insect cells until the viability of the insect cells reaches 10% or less.
摘要:
The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D antigens and their use in vaccines for the prevention of an Enterovirus infection.
摘要:
Some embodiments of the invention include inventive polypeptides (e.g., mutant VP2 proteins) and virus-like particles made from the inventive polypeptides. Other embodiments of the invention include compositions for treating (e.g., preventing) parvovirus (e.g., erythrovirus or parvovirus B19) infection and other diseases. Further embodiments include methods for administering compositions to an animal. Other embodiments include treating (e.g., preventing) par vovirus (e.g., erythrovirus or parvovirus B19) infection and other diseases. Still other embodiments include nucleic acid sequences that encode the inventive polypeptides. Additional embodiments of the invention are also discussed.
摘要:
Some embodiments of the invention include inventive polypeptides (e.g., mutant VP2 proteins) and virus-like particles made from the inventive polypeptides. Other embodiments of the invention include compositions for treating (e.g., preventing) parvovirus (e.g., erythrovirus or parvovirus B19) infection and other diseases. Further embodiments include methods for administering compositions to an animal. Other embodiments include treating (e.g., preventing) par vovirus (e.g., erythrovirus or parvovirus B19) infection and other diseases. Still other embodiments include nucleic acid sequences that encode the inventive polypeptides. Additional embodiments of the invention are also discussed.
摘要翻译:本发明的一些实施方案包括本发明的多肽(E. G.,突变体VP2蛋白)和由本发明的多肽制成病毒样颗粒。 本发明的其他实施方案包括组合物治疗(E. G.防止)细小病毒(E. G. Erythrovirus或细小病毒B19)感染和其它疾病。 进一步的实施例包括用于管理组合物给动物的方法。 其他实施方案包括治疗(例如,预防)比肩vovirus(例如,Erythrovirus或细小病毒B19)感染和其它疾病。 其他实施例包括核酸序列编码所做的本发明的多肽。 本发明的附加实施例被如此讨论。
摘要:
The present invention provides an improved method for the purification of a mixture of complexes comprising a stress protein complexed to a peptide or peptide fragment from a source mixture, typically a cell lysate. The method of the invention provides for protein complexes to be purified using ion exchange chromatography based methods, wherein a modified buffer solution is used which results in the purified stress protein complexes being more immunogenic than protein complexes obtained using conventional methodology. The purified complexes can be used to produce improved vaccine preparations which elicit enhanced immune responses in the subjects to whom the vaccine compositions are administered.
摘要:
The present invention relates to a transfer vector for inserting a gene into a genetic locus of a baculovirus sequence. The transfer vector comprises an expression cassette comprising a eukaryotic promoter operably linked to the gene and a bipartite selection cassette. The present invention also relates to methods of using the transfer vector and derived bacmids and baculoviruses.
摘要:
Viral-based vectors are genetically engineered to express inhibitors of the anti-viral immune system (e.g. inhibitors of the type I interferon response) in order to enhance transgene expression. The transgenes may encode antigens or other therapeutic agents.